Page 2 - Nasdaq Phvs News Today

ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

Pharvaris (NASDAQ:PHVS – Get Free Report)’s share price rose 4.9% during mid-day trading on Friday . The company traded as high as $21.50 and last traded at $21.50. Approximately 3,412 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 45,482 shares. The stock had previously closed at $20.50. […]

Morgan Stanley upgraded shares of Pharvaris (NASDAQ:PHVS – Free Report) from an equal weight rating to an overweight rating in a research report released on Tuesday morning, MarketBeat Ratings reports. The firm currently has $34.00 price objective on the stock, up from their previous price objective of $10.00. Pharvaris Stock Down 5.4 % Shares of […]

Morgan Stanley upgraded shares of Pharvaris (NASDAQ:PHVS – Free Report) from an equal weight rating to an overweight rating in a research note released on Tuesday morning, MarketBeat.com reports. The firm currently has $34.00 target price on the stock, up from their previous target price of $10.00. Pharvaris Stock Performance PHVS opened at $19.32 on […]

Morgan Stanley reaffirmed their equal weight rating on shares of Pharvaris (NASDAQ:PHVS – Free Report) in a research report sent to investors on Monday, Benzinga reports. Morgan Stanley currently has a $10.00 price target on the stock. Separately, JMP Securities lowered their target price on shares of Pharvaris from $23.00 to $20.00 and set a […]

Pharvaris (NASDAQ:PHVS – Get Free Report) was the recipient of a significant decrease in short interest in June. As of June 30th, there was short interest totalling 18,900 shares, a decrease of 47.6% from the June 15th total of 36,100 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average trading […]

Pharvaris (NASDAQ:PHVS – Free Report) was the target of a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 36,100 shares, a drop of 44.4% from the May 31st total of 64,900 shares. Based on an average daily volume of 28,900 shares, the short-interest ratio […]

ZUG, Switzerland, June 20, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization...

Pharvaris (NASDAQ:PHVS – Get Rating) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average […]

Pharvaris (NASDAQ:PHVS – Get Rating) has been given an average recommendation of “Moderate Buy” by the six analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average […]